Patents by Inventor RAVI JAGASIA

RAVI JAGASIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
    Publication number: 20250136984
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: October 2, 2024
    Publication date: May 1, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Lars JOENSON, Søren RASMUSSEN, Disa TEHLER, Dorthe Vang LARSEN, Jesper WORM
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20250116656
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 20, 2023
    Publication date: April 10, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 12259380
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: March 25, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20250051772
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: August 20, 2024
    Publication date: February 13, 2025
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • FUSION PROTEINS TARGETED TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20250034538
    Abstract: The present invention relates to fusion proteins targeted to the central nervous system (CNS) and its use for the treatment of lysosomal storage disorders (LSD).
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Per-Ola Freskgard, Stefan Frost, Alexandra Maria Gehrlein, Ravi Jagasia, Jens Niewoehner, Ralf Thoma
  • Oligonucleotide agonists targeting progranulin
    Patent number: 12203071
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: January 21, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ravi Jagasia, Lars Joenson, Søren Rasmussen, Disa Tehler, Dorthe Vang Larsen, Jesper Worm
  • MODULATORS OF THE G3BP2-TAU INTERACTION FOR THE TREATMENT OF TAU ASSOCIATED DISEASES
    Publication number: 20250000943
    Abstract: Provided are methods for the treatment of a Tau associated disease, comprising administering to a subject an effective amount of a compound modulating a protein-protein interaction between a protein comprising a NTF2-like domain having the amino acid sequence set forth as SEQ ID NO: 3 and Tau protein.
    Type: Application
    Filed: September 12, 2024
    Publication date: January 2, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Marco TERRIGNO, Congwei WANG
  • E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS
    Publication number: 20240345097
    Abstract: The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression.
    Type: Application
    Filed: February 14, 2024
    Publication date: October 17, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Thomas KREMER, Sonja MEIER, Nikhil Janak PANDYA, Stefka Grigorova TYANOVA
  • OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
    Publication number: 20240327837
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Application
    Filed: February 7, 2024
    Publication date: October 3, 2024
    Inventors: Congwei WANG, Christian WEILE, Martin EBELING, Lars JOENSON, Jonas VIKESAA, Ravi JAGASIA, Meiling LI
  • Antisense oligonucleotide for targeting progranulin
    Patent number: 12104153
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: October 1, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • Oligonucleotides targeting RNA binding protein sites
    Patent number: 12084657
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 10, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Congwei Wang, Christian Weile, Martin Ebeling, Lars Joenson, Jonas Vikesaa, Ravi Jagasia, Meiling Li
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20240085402
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 20, 2023
    Publication date: March 14, 2024
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 11852627
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 26, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20230296587
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 21, 2023
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Oligonucleotide Agonists Targeting Progranulin
    Publication number: 20230287412
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: November 14, 2022
    Publication date: September 14, 2023
    Inventors: Ravi Jagasia, Lars Joenson, Soren Rasmussen, Disa Tehler, Dorthe Vang Larsen, Jesper Worm
  • GLUCOCEREBROSIDASE MUTANTS
    Publication number: 20220325265
    Abstract: The present invention provides variants of human ?-Glucocerebrosidase protein.
    Type: Application
    Filed: September 7, 2020
    Publication date: October 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Martin EBELING, Ravi JAGASIA, Nina Marion PFAHLER, Ralf THOMA
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20220204973
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 30, 2022
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20220146496
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 11320421
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS
    Publication number: 20220091137
    Abstract: The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression.
    Type: Application
    Filed: January 15, 2020
    Publication date: March 24, 2022
    Inventors: Veronica Costa, Thomas Peter John Dunkley, Nikhil Janak Pandya, Ravi Jagasia